UA125026C2 - РІДКІ КОМПОЗИЦІЇ (S)-N-(5-((R)-2-(2,5-ДИФТОРФЕНІЛ)ПІРОЛІДИН-1-ІЛ)ПІРАЗОЛО[1,5-a]ПІРИМІДИН-3-ІЛ)-3-ГІДРОКСИПІРОЛІДИН-1-КАРБОКСАМІДУ - Google Patents

Info

Publication number

UA125026C2

UA125026C2 UAA201810093A UAA201810093A UA125026C2 UA 125026 C2 UA125026 C2 UA 125026C2 UA A201810093 A UAA201810093 A UA A201810093A UA A201810093 A UAA201810093 A UA A201810093A UA 125026 C2 UA125026 C2 UA 125026C2

Authority

UA

Ukraine

Prior art keywords

liquid composition

cancer

amount

protein

composition according

Prior art date

2016-04-04

Links

• Espacenet
• Global Dossier
• Discuss

• 239000012669 liquid formulation Substances 0.000 title abstract description 82
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 187
• 201000011510 cancer Diseases 0.000 claims abstract description 136
• 150000003839 salts Chemical class 0.000 claims abstract description 96
• 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims abstract description 62
• 239000000203 mixture Substances 0.000 claims description 267
• 239000007788 liquid Substances 0.000 claims description 180
• 108090000623 proteins and genes Proteins 0.000 claims description 162
• 150000001875 compounds Chemical class 0.000 claims description 127
• 238000000034 method Methods 0.000 claims description 103
• 230000014509 gene expression Effects 0.000 claims description 86
• 102000004169 proteins and genes Human genes 0.000 claims description 83
• 230000000694 effects Effects 0.000 claims description 78
• 239000003795 chemical substances by application Substances 0.000 claims description 76
• 230000008482 dysregulation Effects 0.000 claims description 74
• 235000003599 food sweetener Nutrition 0.000 claims description 67
• 239000003765 sweetening agent Substances 0.000 claims description 67
• 235000013355 food flavoring agent Nutrition 0.000 claims description 52
• 230000035772 mutation Effects 0.000 claims description 51
• 239000000872 buffer Substances 0.000 claims description 43
• 229960000999 sodium citrate dihydrate Drugs 0.000 claims description 35
• HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 35
• 235000019596 Masking bitterness Nutrition 0.000 claims description 34
• 229920000858 Cyclodextrin Polymers 0.000 claims description 33
• 101150052530 Mtk gene Proteins 0.000 claims description 31
• 239000005454 flavour additive Substances 0.000 claims description 30
• 108091000080 Phosphotransferase Proteins 0.000 claims description 27
• 102000020233 phosphotransferase Human genes 0.000 claims description 27
• 102100040421 Treacle protein Human genes 0.000 claims description 26
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 24
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 23
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 22
• 229930006000 Sucrose Natural products 0.000 claims description 22
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 22
• 239000005720 sucrose Substances 0.000 claims description 22
• 230000001404 mediated effect Effects 0.000 claims description 17
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 17
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 16
• 230000002018 overexpression Effects 0.000 claims description 13
• 230000004913 activation Effects 0.000 claims description 12
• 239000001509 sodium citrate Substances 0.000 claims description 12
• 230000005945 translocation Effects 0.000 claims description 12
• 235000011187 glycerol Nutrition 0.000 claims description 11
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 10
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 10
• 230000003321 amplification Effects 0.000 claims description 10
• 238000003199 nucleic acid amplification method Methods 0.000 claims description 10
• 239000000600 sorbitol Substances 0.000 claims description 10
• 235000010356 sorbitol Nutrition 0.000 claims description 10
• PKIDNTKRVKSLDB-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;hydrate Chemical compound O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PKIDNTKRVKSLDB-UHFFFAOYSA-K 0.000 claims description 9
• CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 8
• 229960004106 citric acid Drugs 0.000 claims description 8
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 8
• 229960002216 methylparaben Drugs 0.000 claims description 8
• 239000004302 potassium sorbate Substances 0.000 claims description 8
• 235000010241 potassium sorbate Nutrition 0.000 claims description 8
• 229940069338 potassium sorbate Drugs 0.000 claims description 8
• 239000001488 sodium phosphate Substances 0.000 claims description 8
• 229910000162 sodium phosphate Inorganic materials 0.000 claims description 8
• 238000006467 substitution reaction Methods 0.000 claims description 8
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 8
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 7
• 238000013519 translation Methods 0.000 claims description 7
• 210000000349 chromosome Anatomy 0.000 claims description 6
• 239000004376 Sucralose Substances 0.000 claims description 5
• 235000019408 sucralose Nutrition 0.000 claims description 5
• BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 5
• 239000011093 chipboard Substances 0.000 claims description 3
• 229910052740 iodine Inorganic materials 0.000 claims description 3
• 235000021028 berry Nutrition 0.000 claims description 2
• 235000013399 edible fruits Nutrition 0.000 claims description 2
• 208000036483 hereditary essential 6 tremor Diseases 0.000 claims description 2
• 101710200896 Acyl-CoA thioesterase 2 Proteins 0.000 claims 1
• 241000179924 Chelus Species 0.000 claims 1
• 235000006732 Torreya nucifera Nutrition 0.000 claims 1
• 244000111306 Torreya nucifera Species 0.000 claims 1
• 210000003050 axon Anatomy 0.000 claims 1
• 235000020028 corn beer Nutrition 0.000 claims 1
• 235000015110 jellies Nutrition 0.000 claims 1
• 239000008274 jelly Substances 0.000 claims 1
• 210000004185 liver Anatomy 0.000 claims 1
• 102200027165 rs201383094 Human genes 0.000 claims 1
• 238000009958 sewing Methods 0.000 claims 1
• 208000002193 Pain Diseases 0.000 abstract description 91
• 238000011282 treatment Methods 0.000 abstract description 63
• 206010061218 Inflammation Diseases 0.000 abstract description 10
• 230000004054 inflammatory process Effects 0.000 abstract description 10
• 208000035473 Communicable disease Diseases 0.000 abstract description 7
• 102100036232 PH and SEC7 domain-containing protein 4 Human genes 0.000 description 113
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 48
• 239000000523 sample Substances 0.000 description 47
• 239000000243 solution Substances 0.000 description 45
• 239000002585 base Substances 0.000 description 44
• 239000003814 drug Substances 0.000 description 42
• 239000003112 inhibitor Substances 0.000 description 42
• BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 36
• -1 4-methylpiperidinyl Chemical group 0.000 description 31
• 201000010099 disease Diseases 0.000 description 30
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 26
• 239000007787 solid Substances 0.000 description 26
• 239000002904 solvent Substances 0.000 description 25
• 208000019505 Deglutition disease Diseases 0.000 description 24
• 208000004296 neuralgia Diseases 0.000 description 24
• 239000011541 reaction mixture Substances 0.000 description 24
• 229940124597 therapeutic agent Drugs 0.000 description 23
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
• 238000001959 radiotherapy Methods 0.000 description 22
• 230000001105 regulatory effect Effects 0.000 description 21
• 239000000725 suspension Substances 0.000 description 20
• 238000002360 preparation method Methods 0.000 description 18
• 108700024394 Exon Proteins 0.000 description 17
• 208000035475 disorder Diseases 0.000 description 17
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 16
• 230000037430 deletion Effects 0.000 description 16
• 238000012217 deletion Methods 0.000 description 16
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 16
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 16
• 238000004128 high performance liquid chromatography Methods 0.000 description 15
• 229920001223 polyethylene glycol Polymers 0.000 description 15
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 15
• 238000001356 surgical procedure Methods 0.000 description 15
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 14
• 238000004458 analytical method Methods 0.000 description 14
• 208000021722 neuropathic pain Diseases 0.000 description 14
• 238000002560 therapeutic procedure Methods 0.000 description 14
• 238000004090 dissolution Methods 0.000 description 13
• 230000037361 pathway Effects 0.000 description 13
• 206010009944 Colon cancer Diseases 0.000 description 12
• 206010033701 Papillary thyroid cancer Diseases 0.000 description 12
• 238000002441 X-ray diffraction Methods 0.000 description 12
• 210000004027 cell Anatomy 0.000 description 12
• 239000000796 flavoring agent Substances 0.000 description 12
• 230000001965 increasing effect Effects 0.000 description 12
• 238000003756 stirring Methods 0.000 description 12
• 239000000126 substance Substances 0.000 description 12
• 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 12
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 11
• 206010039491 Sarcoma Diseases 0.000 description 11
• 238000006243 chemical reaction Methods 0.000 description 11
• 230000001684 chronic effect Effects 0.000 description 11
• 238000000113 differential scanning calorimetry Methods 0.000 description 11
• 208000015122 neurodegenerative disease Diseases 0.000 description 11
• 208000024891 symptom Diseases 0.000 description 11
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
• 208000000094 Chronic Pain Diseases 0.000 description 10
• 206010065859 Congenital fibrosarcoma Diseases 0.000 description 10
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 10
• 108010025020 Nerve Growth Factor Proteins 0.000 description 10
• 239000012829 chemotherapy agent Substances 0.000 description 10
• 238000000634 powder X-ray diffraction Methods 0.000 description 10
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 9
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
• 102000007072 Nerve Growth Factors Human genes 0.000 description 9
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
• 208000005298 acute pain Diseases 0.000 description 9
• WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical class OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 9
• 230000037396 body weight Effects 0.000 description 9
• 210000004556 brain Anatomy 0.000 description 9
• 238000002512 chemotherapy Methods 0.000 description 9
• 235000013615 non-nutritive sweetener Nutrition 0.000 description 9
• QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 9
• 239000011734 sodium Substances 0.000 description 9
• QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 9
• 230000009747 swallowing Effects 0.000 description 9
• 206010065390 Inflammatory pain Diseases 0.000 description 8
• 208000005615 Interstitial Cystitis Diseases 0.000 description 8
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 8
• SOQQBSNVBABHLO-UHFFFAOYSA-K O.O.O.O.O.O.C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[K+].[K+].[K+] Chemical compound O.O.O.O.O.O.C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[K+].[K+].[K+] SOQQBSNVBABHLO-UHFFFAOYSA-K 0.000 description 8
• HEOQUHKWXFSWFM-UHFFFAOYSA-H O.O.O.O.O.O.O.[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O Chemical compound O.O.O.O.O.O.O.[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O HEOQUHKWXFSWFM-UHFFFAOYSA-H 0.000 description 8
• PBPOTMMPWKHFDJ-UHFFFAOYSA-K O.O.O.O.O.O.[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O Chemical compound O.O.O.O.O.O.[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O PBPOTMMPWKHFDJ-UHFFFAOYSA-K 0.000 description 8
• MLDABNPMJHISIF-UHFFFAOYSA-H O.O.O.O.O.[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O Chemical compound O.O.O.O.O.[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O MLDABNPMJHISIF-UHFFFAOYSA-H 0.000 description 8
• NKFYBRSYSOPDCZ-UHFFFAOYSA-K O.O.O.O.O.[K+].[K+].[K+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O Chemical compound O.O.O.O.O.[K+].[K+].[K+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O NKFYBRSYSOPDCZ-UHFFFAOYSA-K 0.000 description 8
• LADSWJKRZCQPTH-UHFFFAOYSA-K O.O.O.O.[K+].[K+].[K+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O Chemical compound O.O.O.O.[K+].[K+].[K+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O LADSWJKRZCQPTH-UHFFFAOYSA-K 0.000 description 8
• VNWBMIOGMIMEAL-UHFFFAOYSA-K O.O.O.O.[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O Chemical compound O.O.O.O.[Na+].[Na+].[Na+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O VNWBMIOGMIMEAL-UHFFFAOYSA-K 0.000 description 8
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 8
• 208000024770 Thyroid neoplasm Diseases 0.000 description 8
• 239000008186 active pharmaceutical agent Substances 0.000 description 8
• 230000001154 acute effect Effects 0.000 description 8
• 150000001413 amino acids Chemical class 0.000 description 8
• 238000003556 assay Methods 0.000 description 8
• 229960004679 doxorubicin Drugs 0.000 description 8
• 238000009472 formulation Methods 0.000 description 8
• 238000003364 immunohistochemistry Methods 0.000 description 8
• 229940043355 kinase inhibitor Drugs 0.000 description 8
• 238000007481 next generation sequencing Methods 0.000 description 8
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 8
• SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 8
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
• 229940050931 potassium citrate monohydrate Drugs 0.000 description 8
• 229910052708 sodium Inorganic materials 0.000 description 8
• 210000004872 soft tissue Anatomy 0.000 description 8
• 238000001179 sorption measurement Methods 0.000 description 8
• 235000000346 sugar Nutrition 0.000 description 8
• 208000011580 syndromic disease Diseases 0.000 description 8
• BYGHBKRGJLNJFU-UHFFFAOYSA-H tricalcium 2-hydroxypropane-1,2,3-tricarboxylate dihydrate Chemical compound O.O.[Ca++].[Ca++].[Ca++].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O BYGHBKRGJLNJFU-UHFFFAOYSA-H 0.000 description 8
• OHGJCWABWSRBNC-UHFFFAOYSA-H tricalcium;2-hydroxypropane-1,2,3-tricarboxylate;hydrate Chemical compound O.[Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O OHGJCWABWSRBNC-UHFFFAOYSA-H 0.000 description 8
• HFNBEHZHDROQEC-UHFFFAOYSA-H tricalcium;2-hydroxypropane-1,2,3-tricarboxylate;trihydrate Chemical compound O.O.O.[Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HFNBEHZHDROQEC-UHFFFAOYSA-H 0.000 description 8
• SJYANGXRYLBKSA-UHFFFAOYSA-K tripotassium 2-hydroxypropane-1,2,3-tricarboxylate heptahydrate Chemical compound O.O.O.O.O.O.O.[K+].[K+].[K+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O SJYANGXRYLBKSA-UHFFFAOYSA-K 0.000 description 8
• LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 8
• OBKARMSLSGWHQK-UHFFFAOYSA-K tripotassium;2-hydroxypropane-1,2,3-tricarboxylate;dihydrate Chemical compound O.O.[K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O OBKARMSLSGWHQK-UHFFFAOYSA-K 0.000 description 8
• PVNSIYAUPJNAMQ-UHFFFAOYSA-K trisodium 2-hydroxypropane-1,2,3-tricarboxylate heptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PVNSIYAUPJNAMQ-UHFFFAOYSA-K 0.000 description 8
• DVBIMNUZCMCPRL-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O DVBIMNUZCMCPRL-UHFFFAOYSA-K 0.000 description 8
• POZPMIFKBAEGSS-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;trihydrate Chemical compound O.O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O POZPMIFKBAEGSS-UHFFFAOYSA-K 0.000 description 8
• TUMCWFMHZOUPDA-UHFFFAOYSA-N 2-ethylsulfanyl-1,3-benzothiazol-6-amine Chemical compound C1=C(N)C=C2SC(SCC)=NC2=C1 TUMCWFMHZOUPDA-UHFFFAOYSA-N 0.000 description 7
• 208000008035 Back Pain Diseases 0.000 description 7
• 201000008808 Fibrosarcoma Diseases 0.000 description 7
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 7
• 206010018338 Glioma Diseases 0.000 description 7
• 241000124008 Mammalia Species 0.000 description 7
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 7
• 206010029240 Neuritis Diseases 0.000 description 7
• 239000002253 acid Substances 0.000 description 7
• 230000027455 binding Effects 0.000 description 7
• 230000015572 biosynthetic process Effects 0.000 description 7
• 239000003153 chemical reaction reagent Substances 0.000 description 7
• 239000007979 citrate buffer Substances 0.000 description 7
• 238000001816 cooling Methods 0.000 description 7
• 230000006378 damage Effects 0.000 description 7
• 229960002949 fluorouracil Drugs 0.000 description 7
• 201000005249 lung adenocarcinoma Diseases 0.000 description 7
• 238000004519 manufacturing process Methods 0.000 description 7
• 201000006417 multiple sclerosis Diseases 0.000 description 7
• 238000010992 reflux Methods 0.000 description 7
• 201000002510 thyroid cancer Diseases 0.000 description 7
• UCCRMEIIRRVQNN-UHFFFAOYSA-H tricalcium 2-hydroxypropane-1,2,3-tricarboxylate hexahydrate Chemical compound O.O.O.O.O.O.C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[Ca+2].C(CC(O)(C(=O)[O-])CC(=O)[O-])(=O)[O-].[Ca+2].[Ca+2] UCCRMEIIRRVQNN-UHFFFAOYSA-H 0.000 description 7
• MCWYAHIQJSBPDX-UHFFFAOYSA-K tripotassium 2-hydroxypropane-1,2,3-tricarboxylate trihydrate Chemical compound O.O.O.[K+].[K+].[K+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O MCWYAHIQJSBPDX-UHFFFAOYSA-K 0.000 description 7
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 7
• 229960004528 vincristine Drugs 0.000 description 7
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 7
• 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 6
• 241000726103 Atta Species 0.000 description 6
• 206010006187 Breast cancer Diseases 0.000 description 6
• 208000026310 Breast neoplasm Diseases 0.000 description 6
• 206010027452 Metastases to bone Diseases 0.000 description 6
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
• 206010029260 Neuroblastoma Diseases 0.000 description 6
• 208000018737 Parkinson disease Diseases 0.000 description 6
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
• 208000006011 Stroke Diseases 0.000 description 6
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
• 229960000397 bevacizumab Drugs 0.000 description 6
• 238000001574 biopsy Methods 0.000 description 6
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
• 229960005395 cetuximab Drugs 0.000 description 6
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 6
• 229960004316 cisplatin Drugs 0.000 description 6
• 235000015165 citric acid Nutrition 0.000 description 6
• 230000037011 constitutive activity Effects 0.000 description 6
• 239000013078 crystal Substances 0.000 description 6
• 230000007423 decrease Effects 0.000 description 6
• 239000008367 deionised water Substances 0.000 description 6
• 229910021641 deionized water Inorganic materials 0.000 description 6
• 238000003745 diagnosis Methods 0.000 description 6
• 239000012458 free base Substances 0.000 description 6
• 230000004927 fusion Effects 0.000 description 6
• 238000004817 gas chromatography Methods 0.000 description 6
• 230000003993 interaction Effects 0.000 description 6
• 229960005386 ipilimumab Drugs 0.000 description 6
• 201000001441 melanoma Diseases 0.000 description 6
• 108020004999 messenger RNA Proteins 0.000 description 6
• BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 6
• 210000000214 mouth Anatomy 0.000 description 6
• 239000012071 phase Substances 0.000 description 6
• 229920001184 polypeptide Polymers 0.000 description 6
• 239000002244 precipitate Substances 0.000 description 6
• 102000004196 processed proteins & peptides Human genes 0.000 description 6
• 108090000765 processed proteins & peptides Proteins 0.000 description 6
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 6
• 230000002285 radioactive effect Effects 0.000 description 6
• 229960005562 radium-223 Drugs 0.000 description 6
• HCWPIIXVSYCSAN-OIOBTWANSA-N radium-223 Chemical compound [223Ra] HCWPIIXVSYCSAN-OIOBTWANSA-N 0.000 description 6
• 230000019491 signal transduction Effects 0.000 description 6
• 235000011008 sodium phosphates Nutrition 0.000 description 6
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 5
• HTFVKMHFUBCIMH-UHFFFAOYSA-N 1,3,5-triiodo-1,3,5-triazinane-2,4,6-trione Chemical compound IN1C(=O)N(I)C(=O)N(I)C1=O HTFVKMHFUBCIMH-UHFFFAOYSA-N 0.000 description 5
• 102100022014 Angiopoietin-1 receptor Human genes 0.000 description 5
• 206010003571 Astrocytoma Diseases 0.000 description 5
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 5
• 206010019233 Headaches Diseases 0.000 description 5
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
• FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 5
• 239000005551 L01XE03 - Erlotinib Substances 0.000 description 5
• 239000002147 L01XE04 - Sunitinib Substances 0.000 description 5
• 239000002138 L01XE21 - Regorafenib Substances 0.000 description 5
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 5
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 5
• 239000004743 Polypropylene Substances 0.000 description 5
• 102100040177 Tyrosine-protein kinase Tec Human genes 0.000 description 5
• 229960005310 aldesleukin Drugs 0.000 description 5
• 108700025316 aldesleukin Proteins 0.000 description 5
• 230000003305 autocrine Effects 0.000 description 5
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 5
• 210000000988 bone and bone Anatomy 0.000 description 5
• 201000007452 breast secretory carcinoma Diseases 0.000 description 5
• 229960004562 carboplatin Drugs 0.000 description 5
• 229960004397 cyclophosphamide Drugs 0.000 description 5
• 229960003901 dacarbazine Drugs 0.000 description 5
• 229960003668 docetaxel Drugs 0.000 description 5
• 229940079593 drug Drugs 0.000 description 5
• 229960001433 erlotinib Drugs 0.000 description 5
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 5
• 210000003238 esophagus Anatomy 0.000 description 5
• 229960005420 etoposide Drugs 0.000 description 5
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 5
• 239000004744 fabric Substances 0.000 description 5
• 235000019634 flavors Nutrition 0.000 description 5
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 5
• 229960005277 gemcitabine Drugs 0.000 description 5
• 231100000869 headache Toxicity 0.000 description 5
• 239000012535 impurity Substances 0.000 description 5
• 208000014674 injury Diseases 0.000 description 5
• 229940079322 interferon Drugs 0.000 description 5
• 229940036571 iodine therapy Drugs 0.000 description 5
• 229940001447 lactate Drugs 0.000 description 5
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 5
• 238000002844 melting Methods 0.000 description 5
• 230000008018 melting Effects 0.000 description 5
• 229960000485 methotrexate Drugs 0.000 description 5
• 229960004857 mitomycin Drugs 0.000 description 5
• ODLHGICHYURWBS-FOSILIAISA-N molport-023-220-444 Chemical compound CC(O)COC[C@@H]([C@@H]([C@H]([C@@H]1O)O)O[C@@H]2O[C@H]([C@H](O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O3)[C@@H](O)[C@@H]2O)COCC(O)C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@H]3O[C@H]1COCC(C)O ODLHGICHYURWBS-FOSILIAISA-N 0.000 description 5
• 230000004770 neurodegeneration Effects 0.000 description 5
• 229910052757 nitrogen Inorganic materials 0.000 description 5
• 239000012044 organic layer Substances 0.000 description 5
• 229960001756 oxaliplatin Drugs 0.000 description 5
• 229960001592 paclitaxel Drugs 0.000 description 5
• 208000008443 pancreatic carcinoma Diseases 0.000 description 5
• 210000003800 pharynx Anatomy 0.000 description 5
• 238000001907 polarising light microscopy Methods 0.000 description 5
• 229920001155 polypropylene Polymers 0.000 description 5
• 239000000047 product Substances 0.000 description 5
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 5
• 102000005962 receptors Human genes 0.000 description 5
• 108020003175 receptors Proteins 0.000 description 5
• 230000009467 reduction Effects 0.000 description 5
• 229960004836 regorafenib Drugs 0.000 description 5
• FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 5
• 230000004044 response Effects 0.000 description 5
• 206010039073 rheumatoid arthritis Diseases 0.000 description 5
• 208000020431 spinal cord injury Diseases 0.000 description 5
• 229960001796 sunitinib Drugs 0.000 description 5
• WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 5
• 229940095064 tartrate Drugs 0.000 description 5
• 230000000451 tissue damage Effects 0.000 description 5
• 231100000827 tissue damage Toxicity 0.000 description 5
• 229960004066 trametinib Drugs 0.000 description 5
• LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 5
• 229960003862 vemurafenib Drugs 0.000 description 5
• GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 5
• CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 4
• QIZHVCUPPAMGIW-UHFFFAOYSA-N 5-(2,5-difluorophenyl)-3,4-dihydro-2h-pyrrole Chemical compound FC1=CC=C(F)C(C=2CCCN=2)=C1 QIZHVCUPPAMGIW-UHFFFAOYSA-N 0.000 description 4
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 4
• 108010006654 Bleomycin Proteins 0.000 description 4
• 208000010392 Bone Fractures Diseases 0.000 description 4
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
• 206010058019 Cancer Pain Diseases 0.000 description 4
• GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 4
• GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 4
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 4
• 208000032131 Diabetic Neuropathies Diseases 0.000 description 4
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
• HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 4
• 208000001640 Fibromyalgia Diseases 0.000 description 4
• 208000032612 Glial tumor Diseases 0.000 description 4
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 4
• 239000005411 L01XE02 - Gefitinib Substances 0.000 description 4
• 239000003798 L01XE11 - Pazopanib Substances 0.000 description 4
• 239000002146 L01XE16 - Crizotinib Substances 0.000 description 4
• 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 4
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 4
• 208000008930 Low Back Pain Diseases 0.000 description 4
• 241000699670 Mus sp. Species 0.000 description 4
• 208000003076 Osteolysis Diseases 0.000 description 4
• 208000001132 Osteoporosis Diseases 0.000 description 4
• 206010033128 Ovarian cancer Diseases 0.000 description 4
• 206010061535 Ovarian neoplasm Diseases 0.000 description 4
• 229930012538 Paclitaxel Natural products 0.000 description 4
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
• 206010035226 Plasma cell myeloma Diseases 0.000 description 4
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
• 206010060862 Prostate cancer Diseases 0.000 description 4
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
• 102000001708 Protein Isoforms Human genes 0.000 description 4
• 108010029485 Protein Isoforms Proteins 0.000 description 4
• 102000001253 Protein Kinase Human genes 0.000 description 4
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 4
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 4
• 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 4
• 206010061934 Salivary gland cancer Diseases 0.000 description 4
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
• 208000021712 Soft tissue sarcoma Diseases 0.000 description 4
• BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 4
• CEADJUIGVMITSR-UHFFFAOYSA-K [Li+].[Li+].[Li+].O.O.O.O.O.O.O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O Chemical compound [Li+].[Li+].[Li+].O.O.O.O.O.O.O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O CEADJUIGVMITSR-UHFFFAOYSA-K 0.000 description 4
• QAUJGNZFUUOOAF-UHFFFAOYSA-K [Li+].[Li+].[Li+].O.O.O.O.O.O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O Chemical compound [Li+].[Li+].[Li+].O.O.O.O.O.O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O QAUJGNZFUUOOAF-UHFFFAOYSA-K 0.000 description 4
• FMEZOJFOJAGTSX-UHFFFAOYSA-K [Li+].[Li+].[Li+].O.O.O.O.O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O Chemical compound [Li+].[Li+].[Li+].O.O.O.O.O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O FMEZOJFOJAGTSX-UHFFFAOYSA-K 0.000 description 4
• RVZWOOMUSWEJCM-UHFFFAOYSA-K [Li+].[Li+].[Li+].O.O.O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O Chemical compound [Li+].[Li+].[Li+].O.O.O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O RVZWOOMUSWEJCM-UHFFFAOYSA-K 0.000 description 4
• IKWTVSLWAPBBKU-UHFFFAOYSA-N a1010_sial Chemical compound O=[As]O[As]=O IKWTVSLWAPBBKU-UHFFFAOYSA-N 0.000 description 4
• 239000000654 additive Substances 0.000 description 4
• 230000000996 additive effect Effects 0.000 description 4
• 229960002833 aflibercept Drugs 0.000 description 4
• 108010081667 aflibercept Proteins 0.000 description 4
• 229960002594 arsenic trioxide Drugs 0.000 description 4
• GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 4
• 229960001561 bleomycin Drugs 0.000 description 4
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 4
• 208000029028 brain injury Diseases 0.000 description 4
• BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 description 4
• 229960001573 cabazitaxel Drugs 0.000 description 4
• 229960001292 cabozantinib Drugs 0.000 description 4
• ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 4
• VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 4
• 239000001639 calcium acetate Substances 0.000 description 4
• 235000011092 calcium acetate Nutrition 0.000 description 4
• 229960005147 calcium acetate Drugs 0.000 description 4
• MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 4
• 239000001527 calcium lactate Substances 0.000 description 4
• 235000011086 calcium lactate Nutrition 0.000 description 4
• 229960002401 calcium lactate Drugs 0.000 description 4
• 239000001506 calcium phosphate Substances 0.000 description 4
• 229910000389 calcium phosphate Inorganic materials 0.000 description 4
• 235000011010 calcium phosphates Nutrition 0.000 description 4
• GUPPESBEIQALOS-UHFFFAOYSA-L calcium tartrate Chemical compound [Ca+2].[O-]C(=O)C(O)C(O)C([O-])=O GUPPESBEIQALOS-UHFFFAOYSA-L 0.000 description 4
• 239000001427 calcium tartrate Substances 0.000 description 4
• 235000011035 calcium tartrate Nutrition 0.000 description 4
• HDRTWMBOUSPQON-ODZAUARKSA-L calcium;(z)-but-2-enedioate Chemical compound [Ca+2].[O-]C(=O)\C=C/C([O-])=O HDRTWMBOUSPQON-ODZAUARKSA-L 0.000 description 4
• PBUBJNYXWIDFMU-UHFFFAOYSA-L calcium;butanedioate Chemical compound [Ca+2].[O-]C(=O)CCC([O-])=O PBUBJNYXWIDFMU-UHFFFAOYSA-L 0.000 description 4
• 229960004117 capecitabine Drugs 0.000 description 4
• 230000008859 change Effects 0.000 description 4
• 229960005061 crizotinib Drugs 0.000 description 4
• KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 4
• 229960000684 cytarabine Drugs 0.000 description 4
• 238000011393 cytotoxic chemotherapy Methods 0.000 description 4
• 229960002465 dabrafenib Drugs 0.000 description 4
• BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 4
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 4
• 229960000975 daunorubicin Drugs 0.000 description 4
• 238000001514 detection method Methods 0.000 description 4
• JCCYXJAEFHYHPP-OLXYHTOASA-L dilithium;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Li+].[Li+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O JCCYXJAEFHYHPP-OLXYHTOASA-L 0.000 description 4
• PMUKAEUGVCXPDF-UAIGNFCESA-L dilithium;(z)-but-2-enedioate Chemical compound [Li+].[Li+].[O-]C(=O)\C=C/C([O-])=O PMUKAEUGVCXPDF-UAIGNFCESA-L 0.000 description 4
• SHPKCSFVQGSAJU-UAIGNFCESA-L dipotassium;(z)-but-2-enedioate Chemical compound [K+].[K+].[O-]C(=O)\C=C/C([O-])=O SHPKCSFVQGSAJU-UAIGNFCESA-L 0.000 description 4
• CVOQYKPWIVSMDC-UHFFFAOYSA-L dipotassium;butanedioate Chemical compound [K+].[K+].[O-]C(=O)CCC([O-])=O CVOQYKPWIVSMDC-UHFFFAOYSA-L 0.000 description 4
• MSJMDZAOKORVFC-UAIGNFCESA-L disodium maleate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C/C([O-])=O MSJMDZAOKORVFC-UAIGNFCESA-L 0.000 description 4
• 229960005167 everolimus Drugs 0.000 description 4
• 238000001914 filtration Methods 0.000 description 4
• 239000012634 fragment Substances 0.000 description 4
• 239000008369 fruit flavor Substances 0.000 description 4
• 239000007789 gas Substances 0.000 description 4
• 229960002584 gefitinib Drugs 0.000 description 4
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 4
• 208000005017 glioblastoma Diseases 0.000 description 4
• 210000000987 immune system Anatomy 0.000 description 4
• 208000015181 infectious disease Diseases 0.000 description 4
• 230000002401 inhibitory effect Effects 0.000 description 4
• 229960004768 irinotecan Drugs 0.000 description 4
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 4
• 239000010410 layer Substances 0.000 description 4
• 230000000670 limiting effect Effects 0.000 description 4
• XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 4
• 229910001386 lithium phosphate Inorganic materials 0.000 description 4
• WAHQBNXSPALNEA-UHFFFAOYSA-L lithium succinate Chemical compound [Li+].[Li+].[O-]C(=O)CCC([O-])=O WAHQBNXSPALNEA-UHFFFAOYSA-L 0.000 description 4
• 229960004254 lithium succinate Drugs 0.000 description 4
• GKQWYZBANWAFMQ-UHFFFAOYSA-M lithium;2-hydroxypropanoate Chemical compound [Li+].CC(O)C([O-])=O GKQWYZBANWAFMQ-UHFFFAOYSA-M 0.000 description 4
• WNCZOFYWLAPNSS-UHFFFAOYSA-M lithium;3-carboxy-3,5-dihydroxy-5-oxopentanoate Chemical compound [Li+].OC(=O)CC(O)(C(O)=O)CC([O-])=O WNCZOFYWLAPNSS-UHFFFAOYSA-M 0.000 description 4
• 229960002247 lomustine Drugs 0.000 description 4
• 208000030173 low grade glioma Diseases 0.000 description 4
• 208000029791 lytic metastatic bone lesion Diseases 0.000 description 4
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
• 239000000463 material Substances 0.000 description 4
• 238000005259 measurement Methods 0.000 description 4
• 210000005036 nerve Anatomy 0.000 description 4
• 230000000926 neurological effect Effects 0.000 description 4
• 229960003301 nivolumab Drugs 0.000 description 4
• 201000008482 osteoarthritis Diseases 0.000 description 4
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 4
• 201000002528 pancreatic cancer Diseases 0.000 description 4
• 229960000639 pazopanib Drugs 0.000 description 4
• CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 4
• 229960002621 pembrolizumab Drugs 0.000 description 4
• 229960005079 pemetrexed Drugs 0.000 description 4
• QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 description 4
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
• 230000000704 physical effect Effects 0.000 description 4
• 239000011148 porous material Substances 0.000 description 4
• AVTYONGGKAJVTE-OLXYHTOASA-L potassium L-tartrate Chemical compound [K+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O AVTYONGGKAJVTE-OLXYHTOASA-L 0.000 description 4
• 235000011056 potassium acetate Nutrition 0.000 description 4
• 229910000027 potassium carbonate Inorganic materials 0.000 description 4
• 235000011181 potassium carbonates Nutrition 0.000 description 4
• PHZLMBHDXVLRIX-UHFFFAOYSA-M potassium lactate Chemical compound [K+].CC(O)C([O-])=O PHZLMBHDXVLRIX-UHFFFAOYSA-M 0.000 description 4
• 239000001521 potassium lactate Substances 0.000 description 4
• 235000011085 potassium lactate Nutrition 0.000 description 4
• 229960001304 potassium lactate Drugs 0.000 description 4
• 229910000160 potassium phosphate Inorganic materials 0.000 description 4
• 235000011009 potassium phosphates Nutrition 0.000 description 4
• 239000001472 potassium tartrate Substances 0.000 description 4
• 229940111695 potassium tartrate Drugs 0.000 description 4
• 235000011005 potassium tartrates Nutrition 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• 108060006633 protein kinase Proteins 0.000 description 4
• 150000003230 pyrimidines Chemical class 0.000 description 4
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 4
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 4
• 229920006395 saturated elastomer Polymers 0.000 description 4
• 230000011664 signaling Effects 0.000 description 4
• HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 4
• 239000001632 sodium acetate Substances 0.000 description 4
• 235000017281 sodium acetate Nutrition 0.000 description 4
• 239000001540 sodium lactate Substances 0.000 description 4
• 235000011088 sodium lactate Nutrition 0.000 description 4
• 229940005581 sodium lactate Drugs 0.000 description 4
• 229940074404 sodium succinate Drugs 0.000 description 4
• ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 4
• 239000001433 sodium tartrate Substances 0.000 description 4
• 229960002167 sodium tartrate Drugs 0.000 description 4
• 235000011004 sodium tartrates Nutrition 0.000 description 4
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
• 229960004964 temozolomide Drugs 0.000 description 4
• RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 4
• 238000002411 thermogravimetry Methods 0.000 description 4
• 208000013077 thyroid gland carcinoma Diseases 0.000 description 4
• 229960000575 trastuzumab Drugs 0.000 description 4
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 4
• 206010044652 trigeminal neuralgia Diseases 0.000 description 4
• ZNYNJGDTCCWCCN-UHFFFAOYSA-K trilithium 2-hydroxypropane-1,2,3-tricarboxylate dihydrate Chemical compound [Li+].[Li+].[Li+].O.O.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O ZNYNJGDTCCWCCN-UHFFFAOYSA-K 0.000 description 4
• OSJRPECIECUBOG-UHFFFAOYSA-K trilithium;2-hydroxypropane-1,2,3-tricarboxylate;hydrate Chemical compound [Li+].[Li+].[Li+].O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O OSJRPECIECUBOG-UHFFFAOYSA-K 0.000 description 4
• TWQULNDIKKJZPH-UHFFFAOYSA-K trilithium;phosphate Chemical compound [Li+].[Li+].[Li+].[O-]P([O-])([O-])=O TWQULNDIKKJZPH-UHFFFAOYSA-K 0.000 description 4
• OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-Lutidine Substances CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
• ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
• BDTRIDKONHOQQN-UHFFFAOYSA-N 4h-pyrimidin-5-one Chemical compound O=C1CN=CN=C1 BDTRIDKONHOQQN-UHFFFAOYSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
• 208000024827 Alzheimer disease Diseases 0.000 description 3
• 206010002515 Animal bite Diseases 0.000 description 3
• MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 3
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
• 201000004624 Dermatitis Diseases 0.000 description 3
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 3
• 208000034951 Genetic Translocation Diseases 0.000 description 3
• 238000004566 IR spectroscopy Methods 0.000 description 3
• 108010050904 Interferons Proteins 0.000 description 3
• 102000014150 Interferons Human genes 0.000 description 3
• 206010023256 Juvenile melanoma benign Diseases 0.000 description 3
• 208000027747 Kennedy disease Diseases 0.000 description 3
• 239000005517 L01XE01 - Imatinib Substances 0.000 description 3
• 239000005511 L01XE05 - Sorafenib Substances 0.000 description 3
• 239000002136 L01XE07 - Lapatinib Substances 0.000 description 3
• 239000005536 L01XE08 - Nilotinib Substances 0.000 description 3
• 208000000172 Medulloblastoma Diseases 0.000 description 3
• 206010027476 Metastases Diseases 0.000 description 3
• 241001465754 Metazoa Species 0.000 description 3
• 208000034578 Multiple myelomas Diseases 0.000 description 3
• 101100460719 Mus musculus Noto gene Proteins 0.000 description 3
• 241000232901 Nephroma Species 0.000 description 3
• 208000012902 Nervous system disease Diseases 0.000 description 3
• 206010030155 Oesophageal carcinoma Diseases 0.000 description 3
• 229910019142 PO4 Inorganic materials 0.000 description 3
• 201000007286 Pilocytic astrocytoma Diseases 0.000 description 3
• 206010036376 Postherpetic Neuralgia Diseases 0.000 description 3
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
• 208000033781 Thyroid carcinoma Diseases 0.000 description 3
• 101100187345 Xenopus laevis noto gene Proteins 0.000 description 3
• 230000009692 acute damage Effects 0.000 description 3
• 238000011374 additional therapy Methods 0.000 description 3
• 229910052782 aluminium Inorganic materials 0.000 description 3
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
• 150000001412 amines Chemical class 0.000 description 3
• 230000033115 angiogenesis Effects 0.000 description 3
• 238000010171 animal model Methods 0.000 description 3
• 239000002246 antineoplastic agent Substances 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 230000000903 blocking effect Effects 0.000 description 3
• 210000003169 central nervous system Anatomy 0.000 description 3
• 208000006990 cholangiocarcinoma Diseases 0.000 description 3
• 229940127089 cytotoxic agent Drugs 0.000 description 3
• 238000000354 decomposition reaction Methods 0.000 description 3
• 238000011161 development Methods 0.000 description 3
• 230000018109 developmental process Effects 0.000 description 3
• 208000007784 diverticulitis Diseases 0.000 description 3
• 230000002708 enhancing effect Effects 0.000 description 3
• 201000004101 esophageal cancer Diseases 0.000 description 3
• IDNUEBSJWINEMI-UHFFFAOYSA-N ethyl nitrate Chemical compound CCO[N+]([O-])=O IDNUEBSJWINEMI-UHFFFAOYSA-N 0.000 description 3
• 206010017758 gastric cancer Diseases 0.000 description 3
• 239000003102 growth factor Substances 0.000 description 3
• 201000010536 head and neck cancer Diseases 0.000 description 3
• 208000014829 head and neck neoplasm Diseases 0.000 description 3
• 238000010438 heat treatment Methods 0.000 description 3
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 3
• 239000005457 ice water Substances 0.000 description 3
• 229960002411 imatinib Drugs 0.000 description 3
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 3
• 230000002757 inflammatory effect Effects 0.000 description 3
• 230000005764 inhibitory process Effects 0.000 description 3
• 150000007529 inorganic bases Chemical class 0.000 description 3
• 238000002955 isolation Methods 0.000 description 3
• 229960004891 lapatinib Drugs 0.000 description 3
• BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 3
• 239000003446 ligand Substances 0.000 description 3
• 230000010534 mechanism of action Effects 0.000 description 3
• 229940126601 medicinal product Drugs 0.000 description 3
• 229960005181 morphine Drugs 0.000 description 3
• 201000006938 muscular dystrophy Diseases 0.000 description 3
• 208000025351 nephroma Diseases 0.000 description 3
• 210000002569 neuron Anatomy 0.000 description 3
• 201000001119 neuropathy Diseases 0.000 description 3
• 229960001346 nilotinib Drugs 0.000 description 3
• HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 3
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
• 150000007530 organic bases Chemical class 0.000 description 3
• 230000000010 osteolytic effect Effects 0.000 description 3
• 229960001972 panitumumab Drugs 0.000 description 3
• SZFPYBIJACMNJV-UHFFFAOYSA-N perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 description 3
• 229950010632 perifosine Drugs 0.000 description 3
• 210000001428 peripheral nervous system Anatomy 0.000 description 3
• 208000033808 peripheral neuropathy Diseases 0.000 description 3
• 229960002087 pertuzumab Drugs 0.000 description 3
• AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 3
• 239000010452 phosphate Substances 0.000 description 3
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
• 238000001556 precipitation Methods 0.000 description 3
• 229960004618 prednisone Drugs 0.000 description 3
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 3
• 208000037821 progressive disease Diseases 0.000 description 3
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 3
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 3
• 229960003415 propylparaben Drugs 0.000 description 3
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 3
• 230000002829 reductive effect Effects 0.000 description 3
• 239000013049 sediment Substances 0.000 description 3
• 229960002930 sirolimus Drugs 0.000 description 3
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
• 210000003625 skull Anatomy 0.000 description 3
• 229960003787 sorafenib Drugs 0.000 description 3
• 206010041823 squamous cell carcinoma Diseases 0.000 description 3
• 239000008223 sterile water Substances 0.000 description 3
• 238000003860 storage Methods 0.000 description 3
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 3
• 230000001360 synchronised effect Effects 0.000 description 3
• 239000006188 syrup Substances 0.000 description 3
• 235000020357 syrup Nutrition 0.000 description 3
• 230000008685 targeting Effects 0.000 description 3
• 238000012360 testing method Methods 0.000 description 3
• 210000001519 tissue Anatomy 0.000 description 3
• 208000004371 toothache Diseases 0.000 description 3
• 230000008733 trauma Effects 0.000 description 3
• 239000013638 trimer Substances 0.000 description 3
• 239000000230 xanthan gum Substances 0.000 description 3
• 229920001285 xanthan gum Polymers 0.000 description 3
• 235000010493 xanthan gum Nutrition 0.000 description 3
• 229940082509 xanthan gum Drugs 0.000 description 3
• JSDBKAHWADVXFU-UHFFFAOYSA-N 1,3-dimethyluracil Chemical compound CN1C=CC(=O)N(C)C1=O JSDBKAHWADVXFU-UHFFFAOYSA-N 0.000 description 2
• JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical compound NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 description 2
• WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
• 206010001935 American trypanosomiasis Diseases 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
• 206010005949 Bone cancer Diseases 0.000 description 2
• 208000020084 Bone disease Diseases 0.000 description 2
• 208000018084 Bone neoplasm Diseases 0.000 description 2
• 241000167854 Bourreria succulenta Species 0.000 description 2
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
• 208000024699 Chagas disease Diseases 0.000 description 2
• 206010008479 Chest Pain Diseases 0.000 description 2
• 208000016718 Chromosome Inversion Diseases 0.000 description 2
• 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 2
• 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 2
• SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
• 206010012438 Dermatitis atopic Diseases 0.000 description 2
• 206010061818 Disease progression Diseases 0.000 description 2
• 206010013935 Dysmenorrhoea Diseases 0.000 description 2
• 241000168022 Elaphurus davidianus Species 0.000 description 2
• 208000001730 Familial dysautonomia Diseases 0.000 description 2
• 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 2
• 201000010915 Glioblastoma multiforme Diseases 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 2
• 101150017040 I gene Proteins 0.000 description 2
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
• 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 2
• 201000003803 Inflammatory myofibroblastic tumor Diseases 0.000 description 2
• 206010067917 Inflammatory myofibroblastic tumour Diseases 0.000 description 2
• 108010078049 Interferon alpha-2 Proteins 0.000 description 2
• 208000008839 Kidney Neoplasms Diseases 0.000 description 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
• UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 description 2
• 206010025323 Lymphomas Diseases 0.000 description 2
• 102100025912 Melanopsin Human genes 0.000 description 2
• 235000006679 Mentha X verticillata Nutrition 0.000 description 2
• 235000002899 Mentha suaveolens Nutrition 0.000 description 2
• 235000001636 Mentha x rotundifolia Nutrition 0.000 description 2
• 206010070665 Mesoblastic nephroma Diseases 0.000 description 2
• 208000019695 Migraine disease Diseases 0.000 description 2
• 206010028116 Mucosal inflammation Diseases 0.000 description 2
• 201000010927 Mucositis Diseases 0.000 description 2
• XKFTZKGMDDZMJI-HSZRJFAPSA-N N-[5-[(2R)-2-methoxy-1-oxo-2-phenylethyl]-4,6-dihydro-1H-pyrrolo[3,4-c]pyrazol-3-yl]-4-(4-methyl-1-piperazinyl)benzamide Chemical compound O=C([C@H](OC)C=1C=CC=CC=1)N(CC=12)CC=1NN=C2NC(=O)C(C=C1)=CC=C1N1CCN(C)CC1 XKFTZKGMDDZMJI-HSZRJFAPSA-N 0.000 description 2
• 208000025966 Neurological disease Diseases 0.000 description 2
• 208000004983 Phantom Limb Diseases 0.000 description 2
• 206010056238 Phantom pain Diseases 0.000 description 2
• 208000033526 Proximal spinal muscular atrophy type 3 Diseases 0.000 description 2
• 201000004681 Psoriasis Diseases 0.000 description 2
• LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
• REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
• 241000700159 Rattus Species 0.000 description 2
• 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 2
• 102000006382 Ribonucleases Human genes 0.000 description 2
• 108010083644 Ribonucleases Proteins 0.000 description 2
• 201000001638 Riley-Day syndrome Diseases 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
• 208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 description 2
• 206010072450 Spitzoid melanoma Diseases 0.000 description 2
• 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 2
• 208000005718 Stomach Neoplasms Diseases 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
• 108010009978 Tec protein-tyrosine kinase Proteins 0.000 description 2
• CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 2
• 206010043515 Throat cancer Diseases 0.000 description 2
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
• 241000223109 Trypanosoma cruzi Species 0.000 description 2
• 206010045515 Undifferentiated sarcoma Diseases 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 208000027418 Wounds and injury Diseases 0.000 description 2
• 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 2
• 239000008351 acetate buffer Substances 0.000 description 2
• 208000009956 adenocarcinoma Diseases 0.000 description 2
• 230000002411 adverse Effects 0.000 description 2
• 229960001686 afatinib Drugs 0.000 description 2
• ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 2
• 230000032683 aging Effects 0.000 description 2
• HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 2
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
• 230000005775 apoptotic pathway Effects 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 239000008122 artificial sweetener Substances 0.000 description 2
• 235000021311 artificial sweeteners Nutrition 0.000 description 2
• 208000006673 asthma Diseases 0.000 description 2
• 201000008937 atopic dermatitis Diseases 0.000 description 2
• 208000010668 atopic eczema Diseases 0.000 description 2
• SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 230000033228 biological regulation Effects 0.000 description 2
• 235000019658 bitter taste Nutrition 0.000 description 2
• NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 2
• 229910000020 calcium bicarbonate Inorganic materials 0.000 description 2
• 229910000019 calcium carbonate Inorganic materials 0.000 description 2
• 235000010216 calcium carbonate Nutrition 0.000 description 2
• AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
• 239000000920 calcium hydroxide Substances 0.000 description 2
• 229910001861 calcium hydroxide Inorganic materials 0.000 description 2
• 238000004364 calculation method Methods 0.000 description 2
• 230000000747 cardiac effect Effects 0.000 description 2
• 208000003295 carpal tunnel syndrome Diseases 0.000 description 2
• 208000026106 cerebrovascular disease Diseases 0.000 description 2
• 235000019693 cherries Nutrition 0.000 description 2
• 210000000038 chest Anatomy 0.000 description 2
• 201000010989 colorectal carcinoma Diseases 0.000 description 2
• 238000002648 combination therapy Methods 0.000 description 2
• 239000013065 commercial product Substances 0.000 description 2
• 238000009833 condensation Methods 0.000 description 2
• 230000005494 condensation Effects 0.000 description 2
• 201000008168 congenital mesoblastic nephroma Diseases 0.000 description 2
• 208000010247 contact dermatitis Diseases 0.000 description 2
• 210000003252 cranial fossa middle Anatomy 0.000 description 2
• FEHLGOYZDFFMND-UHFFFAOYSA-N cyclopropane-1,1-dicarboxamide Chemical compound NC(=O)C1(C(N)=O)CC1 FEHLGOYZDFFMND-UHFFFAOYSA-N 0.000 description 2
• 229950002966 danusertib Drugs 0.000 description 2
• 238000001938 differential scanning calorimetry curve Methods 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• 230000005750 disease progression Effects 0.000 description 2
• 238000004821 distillation Methods 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 206010013781 dry mouth Diseases 0.000 description 2
• 238000001035 drying Methods 0.000 description 2
• 210000003027 ear inner Anatomy 0.000 description 2
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 239000006260 foam Substances 0.000 description 2
• 235000019264 food flavour enhancer Nutrition 0.000 description 2
• 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 2
• 210000003128 head Anatomy 0.000 description 2
• 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 2
• 238000009396 hybridization Methods 0.000 description 2
• XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
• 229960001101 ifosfamide Drugs 0.000 description 2
• 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 2
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• 229960003507 interferon alfa-2b Drugs 0.000 description 2
• 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 description 2
• 208000037906 ischaemic injury Diseases 0.000 description 2
• 208000028867 ischemia Diseases 0.000 description 2
• 201000004815 juvenile spinal muscular atrophy Diseases 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 229950001845 lestaurtinib Drugs 0.000 description 2
• 230000004807 localization Effects 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 238000002595 magnetic resonance imaging Methods 0.000 description 2
• 210000005075 mammary gland Anatomy 0.000 description 2
• 230000000873 masking effect Effects 0.000 description 2
• 238000010907 mechanical stirring Methods 0.000 description 2
• 239000013213 metal-organic polyhedra Substances 0.000 description 2
• 230000001394 metastastic effect Effects 0.000 description 2
• 206010061289 metastatic neoplasm Diseases 0.000 description 2
• 229940098779 methanesulfonic acid Drugs 0.000 description 2
• 238000012011 method of payment Methods 0.000 description 2
• QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
• 206010027599 migraine Diseases 0.000 description 2
• 229950009655 milciclib Drugs 0.000 description 2
• 208000005264 motor neuron disease Diseases 0.000 description 2
• RXZMYLDMFYNEIM-UHFFFAOYSA-N n,1,4,4-tetramethyl-8-[4-(4-methylpiperazin-1-yl)anilino]-5h-pyrazolo[4,3-h]quinazoline-3-carboxamide Chemical compound CNC(=O)C1=NN(C)C(C2=N3)=C1C(C)(C)CC2=CN=C3NC(C=C1)=CC=C1N1CCN(C)CC1 RXZMYLDMFYNEIM-UHFFFAOYSA-N 0.000 description 2
• 201000002120 neuroendocrine carcinoma Diseases 0.000 description 2
• 201000011519 neuroendocrine tumor Diseases 0.000 description 2
• 231100000878 neurological injury Toxicity 0.000 description 2
• 230000002981 neuropathic effect Effects 0.000 description 2
• 230000007823 neuropathy Effects 0.000 description 2
• 102000039446 nucleic acids Human genes 0.000 description 2
• 108020004707 nucleic acids Proteins 0.000 description 2
• 150000007523 nucleic acids Chemical class 0.000 description 2
• 230000005868 ontogenesis Effects 0.000 description 2
• 229940005483 opioid analgesics Drugs 0.000 description 2
• 238000000399 optical microscopy Methods 0.000 description 2
• 210000000963 osteoblast Anatomy 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 238000003921 particle size analysis Methods 0.000 description 2
• 239000008177 pharmaceutical agent Substances 0.000 description 2
• 239000008363 phosphate buffer Substances 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• 239000011736 potassium bicarbonate Substances 0.000 description 2
• 235000015497 potassium bicarbonate Nutrition 0.000 description 2
• 229910000028 potassium bicarbonate Inorganic materials 0.000 description 2
• TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 230000002335 preservative effect Effects 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
• 238000000746 purification Methods 0.000 description 2
• 239000008213 purified water Substances 0.000 description 2
• LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
• 238000007789 sealing Methods 0.000 description 2
• 239000002002 slurry Substances 0.000 description 2
• MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 description 2
• 208000002320 spinal muscular atrophy Diseases 0.000 description 2
• 201000011549 stomach cancer Diseases 0.000 description 2
• 239000008362 succinate buffer Substances 0.000 description 2
• 150000008163 sugars Chemical class 0.000 description 2
• 239000004094 surface-active agent Substances 0.000 description 2
• 230000004083 survival effect Effects 0.000 description 2
• 235000019640 taste Nutrition 0.000 description 2
• 229960000235 temsirolimus Drugs 0.000 description 2
• QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 2
• GJJYYMXBCYYXPQ-UHFFFAOYSA-N tert-butyl 2-oxopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1=O GJJYYMXBCYYXPQ-UHFFFAOYSA-N 0.000 description 2
• QUXRUQHCVUUDHV-UHFFFAOYSA-N tert-butyl N-[4-(2,5-difluorophenyl)-4-oxobutyl]carbamate Chemical compound FC1=C(C=C(C=C1)F)C(CCCNC(OC(C)(C)C)=O)=O QUXRUQHCVUUDHV-UHFFFAOYSA-N 0.000 description 2
• 230000001225 therapeutic effect Effects 0.000 description 2
• 229940124788 therapeutic inhibitor Drugs 0.000 description 2
• 210000001685 thyroid gland Anatomy 0.000 description 2
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
• 230000004614 tumor growth Effects 0.000 description 2
• 208000032527 type III spinal muscular atrophy Diseases 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 208000022810 undifferentiated (embryonal) sarcoma Diseases 0.000 description 2
• 230000002792 vascular Effects 0.000 description 2
• 108700026220 vif Genes Proteins 0.000 description 2
• YZOUYRAONFXZSI-SBHWVFSVSA-N (1S,3R,5R,6R,8R,10R,11R,13R,15R,16R,18R,20R,21R,23R,25R,26R,28R,30R,31S,33R,35R,36R,37S,38R,39S,40R,41S,42R,43S,44R,45S,46R,47S,48R,49S)-5,10,15,20,25,30,35-heptakis(hydroxymethyl)-37,39,40,41,42,43,44,45,46,47,48,49-dodecamethoxy-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,38-diol Chemical compound O([C@@H]([C@H]([C@@H]1OC)OC)O[C@H]2[C@@H](O)[C@@H]([C@@H](O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3O)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O[C@@H]3[C@@H](CO)O[C@@H]([C@H]([C@@H]3OC)OC)O3)O[C@@H]2CO)OC)[C@H](CO)[C@H]1O[C@@H]1[C@@H](OC)[C@H](OC)[C@H]3[C@@H](CO)O1 YZOUYRAONFXZSI-SBHWVFSVSA-N 0.000 description 1
• YXTKHLHCVFUPPT-YYFJYKOTSA-N (2s)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1r,2r)-1,2-dimethanidylcyclohexane;5-fluoro-1h-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 description 1
• JHHZLHWJQPUNKB-BYPYZUCNSA-N (3s)-pyrrolidin-3-ol Chemical compound O[C@H]1CCNC1 JHHZLHWJQPUNKB-BYPYZUCNSA-N 0.000 description 1
• UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
• ZXFDJWMFCAEGED-UHFFFAOYSA-N 1-chlorocycloocta-1,5-diene;iridium Chemical class [Ir].ClC1=CCCC=CCC1 ZXFDJWMFCAEGED-UHFFFAOYSA-N 0.000 description 1
• GNNDEPIMDAZHRQ-UHFFFAOYSA-N 1-n'-[4-[2-(cyclopropanecarbonylamino)pyridin-4-yl]oxy-2,5-difluorophenyl]-1-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Chemical compound C1=CC(F)=CC=C1NC(=O)C1(C(=O)NC=2C(=CC(OC=3C=C(NC(=O)C4CC4)N=CC=3)=C(F)C=2)F)CC1 GNNDEPIMDAZHRQ-UHFFFAOYSA-N 0.000 description 1
• OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
• FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
• HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
• XCRCSPKQEDMVBO-UHFFFAOYSA-N 2-bromo-1,4-difluorobenzene Chemical compound FC1=CC=C(F)C(Br)=C1 XCRCSPKQEDMVBO-UHFFFAOYSA-N 0.000 description 1
• DKLQJNUJPSHYQG-UHFFFAOYSA-N 2-cyclohexylacetamide Chemical compound NC(=O)CC1CCCCC1 DKLQJNUJPSHYQG-UHFFFAOYSA-N 0.000 description 1
• JGPJRBWLBUGAQN-UHFFFAOYSA-N 2-ethoxy-2,4,4-trimethylpentane Chemical compound CCOC(C)(C)CC(C)(C)C JGPJRBWLBUGAQN-UHFFFAOYSA-N 0.000 description 1
• LIOLIMKSCNQPLV-UHFFFAOYSA-N 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1C1=NN2C(CC=3C=C4C=CC=NC4=CC=3)=CN=C2N=C1 LIOLIMKSCNQPLV-UHFFFAOYSA-N 0.000 description 1
• NCGRTBNMEWDOSH-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;tetrahydrate Chemical compound O.O.O.O.OC(=O)CC(O)(C(O)=O)CC(O)=O NCGRTBNMEWDOSH-UHFFFAOYSA-N 0.000 description 1
• BSYNFGPFPYSTTM-UHFFFAOYSA-N 2-hydroxypropanoic acid;hydrate Chemical compound O.CC(O)C(O)=O BSYNFGPFPYSTTM-UHFFFAOYSA-N 0.000 description 1
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 description 1
• HVBSAKJJOYLTQU-UHFFFAOYSA-M 4-aminobenzenesulfonate Chemical compound NC1=CC=C(S([O-])(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-M 0.000 description 1
• WUBBRNOQWQTFEX-UHFFFAOYSA-M 4-aminosalicylate(1-) Chemical compound NC1=CC=C(C([O-])=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-M 0.000 description 1
• JFUAWXPBHXKZGA-IBGZPJMESA-N 4-fluoro-2-[(4r)-5,5,5-trifluoro-4-hydroxy-2-methyl-4-(1h-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-yl]phenol Chemical compound C([C@@](O)(CC=1NC2=CN=CC=C2C=1)C(F)(F)F)C(C)(C)C1=CC(F)=CC=C1O JFUAWXPBHXKZGA-IBGZPJMESA-N 0.000 description 1
• AILRADAXUVEEIR-UHFFFAOYSA-N 5-chloro-4-n-(2-dimethylphosphorylphenyl)-2-n-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1P(C)(C)=O AILRADAXUVEEIR-UHFFFAOYSA-N 0.000 description 1
• YLLPAAYZOKXPDB-UHFFFAOYSA-N 5-pyrimidin-2-yl-1h-pyrazol-4-amine Chemical class NC1=CNN=C1C1=NC=CC=N1 YLLPAAYZOKXPDB-UHFFFAOYSA-N 0.000 description 1
• VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• 239000005541 ACE inhibitor Substances 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• 241000208140 Acer Species 0.000 description 1
• WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
• 101710159080 Aconitate hydratase A Proteins 0.000 description 1
• 101710159078 Aconitate hydratase B Proteins 0.000 description 1
• NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
• 102000007469 Actins Human genes 0.000 description 1
• 108010085238 Actins Proteins 0.000 description 1
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
• 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
• 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
• 244000144730 Amygdalus persica Species 0.000 description 1
• 208000000058 Anaplasia Diseases 0.000 description 1
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
• 108020004491 Antisense DNA Proteins 0.000 description 1
• 108020005544 Antisense RNA Proteins 0.000 description 1
• 206010073360 Appendix cancer Diseases 0.000 description 1
• 241000408923 Appia Species 0.000 description 1
• 208000006820 Arthralgia Diseases 0.000 description 1
• 206010003399 Arthropod bite Diseases 0.000 description 1
• 108010011485 Aspartame Proteins 0.000 description 1
• 206010003591 Ataxia Diseases 0.000 description 1
• 102000007371 Ataxin-3 Human genes 0.000 description 1
• 102000014461 Ataxins Human genes 0.000 description 1
• 108010078286 Ataxins Proteins 0.000 description 1
• 208000003950 B-cell lymphoma Diseases 0.000 description 1
• 208000019775 Back disease Diseases 0.000 description 1
• 208000025940 Back injury Diseases 0.000 description 1
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
• KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
• 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 1
• 206010005003 Bladder cancer Diseases 0.000 description 1
• 208000006386 Bone Resorption Diseases 0.000 description 1
• 206010065687 Bone loss Diseases 0.000 description 1
• 206010006002 Bone pain Diseases 0.000 description 1
• 201000006390 Brachial Plexus Neuritis Diseases 0.000 description 1
• 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
• 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
• 206010006542 Bulbar palsy Diseases 0.000 description 1
• 208000029402 Bulbospinal muscular atrophy Diseases 0.000 description 1
• 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 1
• 206010068065 Burning mouth syndrome Diseases 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
• FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
• DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
• 208000005623 Carcinogenesis Diseases 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 208000001387 Causalgia Diseases 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 206010007882 Cellulitis Diseases 0.000 description 1
• 206010064012 Central pain syndrome Diseases 0.000 description 1
• 206010008025 Cerebellar ataxia Diseases 0.000 description 1
• 206010058842 Cerebrovascular insufficiency Diseases 0.000 description 1
• 206010008513 Child maltreatment syndrome Diseases 0.000 description 1
• 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
• 244000241235 Citrullus lanatus Species 0.000 description 1
• 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 1
• 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
• 235000005979 Citrus limon Nutrition 0.000 description 1
• 244000131522 Citrus pyriformis Species 0.000 description 1
• 240000000560 Citrus x paradisi Species 0.000 description 1
• 208000033647 Classic progressive supranuclear palsy syndrome Diseases 0.000 description 1
• 240000007154 Coffea arabica Species 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• 206010010774 Constipation Diseases 0.000 description 1
• 208000034656 Contusions Diseases 0.000 description 1
• 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
• MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
• MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
• 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
• 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
• 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 102000053602 DNA Human genes 0.000 description 1
• 230000004544 DNA amplification Effects 0.000 description 1
• 206010012289 Dementia Diseases 0.000 description 1
• 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
• 208000016192 Demyelinating disease Diseases 0.000 description 1
• 206010012305 Demyelination Diseases 0.000 description 1
• 206010012335 Dependence Diseases 0.000 description 1
• 206010012442 Dermatitis contact Diseases 0.000 description 1
• 208000012184 Diffuse Brain injury Diseases 0.000 description 1
• 208000005171 Dysmenorrhea Diseases 0.000 description 1
• 206010067601 Dysmyelination Diseases 0.000 description 1
• 239000004097 EU approved flavor enhancer Substances 0.000 description 1
• 241000258955 Echinodermata Species 0.000 description 1
• 201000009273 Endometriosis Diseases 0.000 description 1
• 208000004232 Enteritis Diseases 0.000 description 1
• 101800003838 Epidermal growth factor Proteins 0.000 description 1
• 240000006890 Erythroxylum coca Species 0.000 description 1
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
• JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
• 239000001116 FEMA 4028 Substances 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• 240000006927 Foeniculum vulgare Species 0.000 description 1
• 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
• BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
• 206010017076 Fracture Diseases 0.000 description 1
• 201000011240 Frontotemporal dementia Diseases 0.000 description 1
• 229930091371 Fructose Natural products 0.000 description 1
• 239000005715 Fructose Substances 0.000 description 1
• RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
• 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
• 108091006109 GTPases Proteins 0.000 description 1
• 208000037767 Gallbladder pain Diseases 0.000 description 1
• 240000001238 Gaultheria procumbens Species 0.000 description 1
• 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
• 208000003736 Gerstmann-Straussler-Scheinker Disease Diseases 0.000 description 1
• 206010072075 Gerstmann-Straussler-Scheinker syndrome Diseases 0.000 description 1
• 208000021965 Glossopharyngeal Nerve disease Diseases 0.000 description 1
• 240000004670 Glycyrrhiza echinata Species 0.000 description 1
• 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
• 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
• 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
• 201000005569 Gout Diseases 0.000 description 1
• 239000007818 Grignard reagent Substances 0.000 description 1
• 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
• 206010018985 Haemorrhage intracranial Diseases 0.000 description 1
• 206010019196 Head injury Diseases 0.000 description 1
• 208000010496 Heart Arrest Diseases 0.000 description 1
• 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
• 208000023105 Huntington disease Diseases 0.000 description 1
• 208000037147 Hypercalcaemia Diseases 0.000 description 1
• 206010021143 Hypoxia Diseases 0.000 description 1
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
• 208000006877 Insect Bites and Stings Diseases 0.000 description 1
• 206010049949 Intercostal neuralgia Diseases 0.000 description 1
• 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
• 208000008574 Intracranial Hemorrhages Diseases 0.000 description 1
• 240000007049 Juglans regia Species 0.000 description 1
• 235000009496 Juglans regia Nutrition 0.000 description 1
• 238000003109 Karl Fischer titration Methods 0.000 description 1
• 208000000913 Kidney Calculi Diseases 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
• 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 1
• 208000007914 Labor Pain Diseases 0.000 description 1
• 208000035945 Labour pain Diseases 0.000 description 1
• 208000034693 Laceration Diseases 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 108010000817 Leuprolide Proteins 0.000 description 1
• 208000009829 Lewy Body Disease Diseases 0.000 description 1
• 102000004882 Lipase Human genes 0.000 description 1
• 108090001060 Lipase Proteins 0.000 description 1
• 239000004367 Lipase Substances 0.000 description 1
• 208000019693 Lung disease Diseases 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 208000002569 Machado-Joseph Disease Diseases 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
• GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 208000035346 Margins of Excision Diseases 0.000 description 1
• 208000037848 Metastatic bone disease Diseases 0.000 description 1
• 102000029749 Microtubule Human genes 0.000 description 1
• 108091022875 Microtubule Proteins 0.000 description 1
• 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
• 206010027910 Mononeuritis Diseases 0.000 description 1
• 208000002472 Morton Neuroma Diseases 0.000 description 1
• 208000020059 Morton neuralgia Diseases 0.000 description 1
• 208000003445 Mouth Neoplasms Diseases 0.000 description 1
• 208000001089 Multiple system atrophy Diseases 0.000 description 1
• 101100456571 Mus musculus Med12 gene Proteins 0.000 description 1
• 208000008238 Muscle Spasticity Diseases 0.000 description 1
• 208000030858 Myofascial Pain Syndromes Diseases 0.000 description 1
• 108010037801 Myosin-Light-Chain Phosphatase Proteins 0.000 description 1
• 238000005481 NMR spectroscopy Methods 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 206010029148 Nephrolithiasis Diseases 0.000 description 1
• 102000015336 Nerve Growth Factor Human genes 0.000 description 1
• 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
• 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
• 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 1
• 206010029279 Neurogenic bladder Diseases 0.000 description 1
• 208000032452 Nevus, Epithelioid and Spindle Cell Diseases 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
• 238000000636 Northern blotting Methods 0.000 description 1
• 206010068106 Occipital neuralgia Diseases 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 108700020796 Oncogene Proteins 0.000 description 1
• 208000003435 Optic Neuritis Diseases 0.000 description 1
• 206010031009 Oral pain Diseases 0.000 description 1
• 208000010191 Osteitis Deformans Diseases 0.000 description 1
• 102000016979 Other receptors Human genes 0.000 description 1
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
• 208000027868 Paget disease Diseases 0.000 description 1
• 206010033885 Paraparesis Diseases 0.000 description 1
• 208000030852 Parasitic disease Diseases 0.000 description 1
• 208000027089 Parkinsonian disease Diseases 0.000 description 1
• 206010034010 Parkinsonism Diseases 0.000 description 1
• 240000003444 Paullinia cupana Species 0.000 description 1
• 235000000556 Paullinia cupana Nutrition 0.000 description 1
• 208000000450 Pelvic Pain Diseases 0.000 description 1
• 201000007100 Pharyngitis Diseases 0.000 description 1
• 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
• 102100030264 Pleckstrin Human genes 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 206010036105 Polyneuropathy Diseases 0.000 description 1
• 102100023204 Potassium channel subfamily K member 2 Human genes 0.000 description 1
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
• 208000032319 Primary lateral sclerosis Diseases 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 108091000054 Prion Proteins 0.000 description 1
• 102000029797 Prion Human genes 0.000 description 1
• 208000024777 Prion disease Diseases 0.000 description 1
• 102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
• 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 description 1
• XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
• 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
• 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
• 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
• 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
• 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
• 229940079156 Proteasome inhibitor Drugs 0.000 description 1
• 244000018633 Prunus armeniaca Species 0.000 description 1
• 235000009827 Prunus armeniaca Nutrition 0.000 description 1
• 235000006040 Prunus persica var persica Nutrition 0.000 description 1
• 208000003251 Pruritus Diseases 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
• ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
• 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
• 101710105008 RNA-binding protein Proteins 0.000 description 1
• 206010037779 Radiculopathy Diseases 0.000 description 1
• 208000015039 Rapidly involuting congenital hemangioma Diseases 0.000 description 1
• 206010038111 Recurrent cancer Diseases 0.000 description 1
• 206010038389 Renal cancer Diseases 0.000 description 1
• 208000025747 Rheumatic disease Diseases 0.000 description 1
• HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
• PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
• 240000007651 Rubus glaucus Species 0.000 description 1
• 235000011034 Rubus glaucus Nutrition 0.000 description 1
• 235000009122 Rubus idaeus Nutrition 0.000 description 1
• 102100037764 Serine/threonine-protein phosphatase PP1-beta catalytic subunit Human genes 0.000 description 1
• 208000002108 Shaken Baby Syndrome Diseases 0.000 description 1
• 108020004682 Single-Stranded DNA Proteins 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 206010041067 Small cell lung cancer Diseases 0.000 description 1
• 208000004078 Snake Bites Diseases 0.000 description 1
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
• 238000002105 Southern blotting Methods 0.000 description 1
• 208000002548 Spastic Paraparesis Diseases 0.000 description 1
• 208000003589 Spider Bites Diseases 0.000 description 1
• 206010041549 Spinal cord compression Diseases 0.000 description 1
• 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
• 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 1
• 208000005250 Spontaneous Fractures Diseases 0.000 description 1
• 208000010040 Sprains and Strains Diseases 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 208000007107 Stomach Ulcer Diseases 0.000 description 1
• 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
• 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
• 206010042496 Sunburn Diseases 0.000 description 1
• 208000032859 Synucleinopathies Diseases 0.000 description 1
• 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 description 1
• 229920002253 Tannate Polymers 0.000 description 1
• 208000022292 Tay-Sachs disease Diseases 0.000 description 1
• 108010017842 Telomerase Proteins 0.000 description 1
• 208000021945 Tendon injury Diseases 0.000 description 1
• 208000024313 Testicular Neoplasms Diseases 0.000 description 1
• 206010057644 Testis cancer Diseases 0.000 description 1
• 240000006909 Tilia x europaea Species 0.000 description 1
• 235000011941 Tilia x europaea Nutrition 0.000 description 1
• 208000016620 Tourette disease Diseases 0.000 description 1
• 102000005937 Tropomyosin Human genes 0.000 description 1
• 108010030743 Tropomyosin Proteins 0.000 description 1
• 208000025865 Ulcer Diseases 0.000 description 1
• 206010046298 Upper motor neurone lesion Diseases 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• 206010046543 Urinary incontinence Diseases 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• 208000002495 Uterine Neoplasms Diseases 0.000 description 1
• 235000009499 Vanilla fragrans Nutrition 0.000 description 1
• 244000263375 Vanilla tahitensis Species 0.000 description 1
• 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
• 206010047700 Vomiting Diseases 0.000 description 1
• 101100020289 Xenopus laevis koza gene Proteins 0.000 description 1
• 208000005946 Xerostomia Diseases 0.000 description 1
• TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 description 1
• 229960000853 abiraterone Drugs 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 239000000619 acesulfame-K Substances 0.000 description 1
• IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
• PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
• 108010052004 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide Proteins 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 208000006336 acinar cell carcinoma Diseases 0.000 description 1
• 210000004695 acinic cell Anatomy 0.000 description 1
• 229940048053 acrylate Drugs 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 230000002730 additional effect Effects 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 208000037844 advanced solid tumor Diseases 0.000 description 1
• 229960002736 afatinib dimaleate Drugs 0.000 description 1
• USNRYVNRPYXCSP-JUGPPOIOSA-N afatinib dimaleate Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 USNRYVNRPYXCSP-JUGPPOIOSA-N 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
• 150000008041 alkali metal carbonates Chemical class 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• 125000000217 alkyl group Chemical group 0.000 description 1
• 229940100198 alkylating agent Drugs 0.000 description 1
• 239000002168 alkylating agent Substances 0.000 description 1
• HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
• WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
• 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
• 229950005952 altiratinib Drugs 0.000 description 1
• 229940035676 analgesics Drugs 0.000 description 1
• 239000004037 angiogenesis inhibitor Substances 0.000 description 1
• 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
• 230000002491 angiogenic effect Effects 0.000 description 1
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
• 208000022531 anorexia Diseases 0.000 description 1
• 230000003042 antagnostic effect Effects 0.000 description 1
• 239000000730 antalgic agent Substances 0.000 description 1
• 230000002280 anti-androgenic effect Effects 0.000 description 1
• 230000003388 anti-hormonal effect Effects 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 230000000340 anti-metabolite Effects 0.000 description 1
• 239000000051 antiandrogen Substances 0.000 description 1
• 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 229940100197 antimetabolite Drugs 0.000 description 1
• 239000002256 antimetabolite Substances 0.000 description 1
• 239000003816 antisense DNA Substances 0.000 description 1
• 229940076005 apoptosis modulator Drugs 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 208000021780 appendiceal neoplasm Diseases 0.000 description 1
• 239000008365 aqueous carrier Substances 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 229940072107 ascorbate Drugs 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 239000000605 aspartame Substances 0.000 description 1
• 235000010357 aspartame Nutrition 0.000 description 1
• IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
• 229960003438 aspartame Drugs 0.000 description 1
• 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 229950000971 baricitinib Drugs 0.000 description 1
• XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 description 1
• 150000007514 bases Chemical class 0.000 description 1
• 229940077388 benzenesulfonate Drugs 0.000 description 1
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
• SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
• 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
• GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
• 229960004853 betadex Drugs 0.000 description 1
• 230000002146 bilateral effect Effects 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 229950003054 binimetinib Drugs 0.000 description 1
• ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 230000008512 biological response Effects 0.000 description 1
• 229960000074 biopharmaceutical Drugs 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 238000009835 boiling Methods 0.000 description 1
• 230000008468 bone growth Effects 0.000 description 1
• 210000002805 bone matrix Anatomy 0.000 description 1
• 230000010072 bone remodeling Effects 0.000 description 1
• 208000024883 bone remodeling disease Diseases 0.000 description 1
• 230000024279 bone resorption Effects 0.000 description 1
• 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 201000008275 breast carcinoma Diseases 0.000 description 1
• 229950004272 brigatinib Drugs 0.000 description 1
• 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
• 235000010634 bubble gum Nutrition 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229960005069 calcium Drugs 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
• 239000001354 calcium citrate Substances 0.000 description 1
• 230000036952 cancer formation Effects 0.000 description 1
• 229950005852 capmatinib Drugs 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• IQXIUTMSTALSFW-VJFOLWCZSA-N carboplatin paclitaxel Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1.O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 IQXIUTMSTALSFW-VJFOLWCZSA-N 0.000 description 1
• 231100000504 carcinogenesis Toxicity 0.000 description 1
• 239000012159 carrier gas Substances 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 230000022131 cell cycle Effects 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 208000025997 central nervous system neoplasm Diseases 0.000 description 1
• 206010008118 cerebral infarction Diseases 0.000 description 1
• 206010008129 cerebral palsy Diseases 0.000 description 1
• 230000035606 childbirth Effects 0.000 description 1
• KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
• 235000019219 chocolate Nutrition 0.000 description 1
• 201000001352 cholecystitis Diseases 0.000 description 1
• 235000017803 cinnamon Nutrition 0.000 description 1
• 229940001468 citrate Drugs 0.000 description 1
• 235000008957 cocaer Nutrition 0.000 description 1
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
• 235000016213 coffee Nutrition 0.000 description 1
• 235000013353 coffee beverage Nutrition 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 239000003184 complementary RNA Substances 0.000 description 1
• 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
• 230000006835 compression Effects 0.000 description 1
• 238000007906 compression Methods 0.000 description 1
• 238000005094 computer simulation Methods 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 230000009519 contusion Effects 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 238000012937 correction Methods 0.000 description 1
• 229960004544 cortisone Drugs 0.000 description 1
• 239000006184 cosolvent Substances 0.000 description 1
• 208000012790 cranial neuralgia Diseases 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical class OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
• 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 description 1
• 230000002435 cytoreductive effect Effects 0.000 description 1
• 238000011500 cytoreductive surgery Methods 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 239000000824 cytostatic agent Substances 0.000 description 1
• 206010061428 decreased appetite Diseases 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• MEUCPCLKGZSHTA-XYAYPHGZSA-N degarelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CC=1C=CC(NC(=O)[C@H]2NC(=O)NC(=O)C2)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(NC(N)=O)C=C1 MEUCPCLKGZSHTA-XYAYPHGZSA-N 0.000 description 1
• 229960002272 degarelix Drugs 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 230000003412 degenerative effect Effects 0.000 description 1
• 229960001251 denosumab Drugs 0.000 description 1
• 238000003795 desorption Methods 0.000 description 1
• 230000001066 destructive effect Effects 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 238000002050 diffraction method Methods 0.000 description 1
• 238000007865 diluting Methods 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 1
• VDCSGNNYCFPWFK-UHFFFAOYSA-N diphenylsilane Chemical compound C=1C=CC=CC=1[SiH2]C1=CC=CC=C1 VDCSGNNYCFPWFK-UHFFFAOYSA-N 0.000 description 1
• IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
• 150000002016 disaccharides Chemical class 0.000 description 1
• 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
• POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 208000000718 duodenal ulcer Diseases 0.000 description 1
• 201000006549 dyspepsia Diseases 0.000 description 1
• 229920001971 elastomer Polymers 0.000 description 1
• 238000002003 electron diffraction Methods 0.000 description 1
• 238000000921 elemental analysis Methods 0.000 description 1
• 230000003073 embolic effect Effects 0.000 description 1
• 229950001969 encorafenib Drugs 0.000 description 1
• 210000004696 endometrium Anatomy 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 229950000521 entrectinib Drugs 0.000 description 1
• 229960004671 enzalutamide Drugs 0.000 description 1
• WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 1
• 239000002532 enzyme inhibitor Substances 0.000 description 1
• 229940116977 epidermal growth factor Drugs 0.000 description 1
• 230000001037 epileptic effect Effects 0.000 description 1
• 229950000206 estolate Drugs 0.000 description 1
• AFAXGSQYZLGZPG-UHFFFAOYSA-L ethane-1,2-disulfonate Chemical compound [O-]S(=O)(=O)CCS([O-])(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-L 0.000 description 1
• RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
• 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
• 210000003414 extremity Anatomy 0.000 description 1
• 201000006061 fatal familial insomnia Diseases 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 239000000706 filtrate Substances 0.000 description 1
• 238000000799 fluorescence microscopy Methods 0.000 description 1
• MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
• 229960002714 fluticasone Drugs 0.000 description 1
• VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
• 235000008191 folinic acid Nutrition 0.000 description 1
• 239000011672 folinic acid Substances 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 238000012395 formulation development Methods 0.000 description 1
• 238000004108 freeze drying Methods 0.000 description 1
• 229940050411 fumarate Drugs 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
• 229930182830 galactose Natural products 0.000 description 1
• 208000001130 gallstones Diseases 0.000 description 1
• GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
• 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
• 210000000609 ganglia Anatomy 0.000 description 1
• 208000010749 gastric carcinoma Diseases 0.000 description 1
• 201000005917 gastric ulcer Diseases 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 230000004545 gene duplication Effects 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 230000000762 glandular Effects 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 201000005442 glossopharyngeal neuralgia Diseases 0.000 description 1
• 229940124750 glucocorticoid receptor agonist Drugs 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
• 150000004676 glycans Chemical class 0.000 description 1
• 150000004795 grignard reagents Chemical class 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 230000010005 growth-factor like effect Effects 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 230000005802 health problem Effects 0.000 description 1
• 201000011066 hemangioma Diseases 0.000 description 1
• MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
• 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 208000008675 hereditary spastic paraplegia Diseases 0.000 description 1
• 125000000623 heterocyclic group Chemical group 0.000 description 1
• IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
• 239000008123 high-intensity sweetener Substances 0.000 description 1
• 235000012907 honey Nutrition 0.000 description 1
• 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
• IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
• 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 230000000148 hypercalcaemia Effects 0.000 description 1
• 208000030915 hypercalcemia disease Diseases 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 229960001507 ibrutinib Drugs 0.000 description 1
• XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 1
• 229960001680 ibuprofen Drugs 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 150000005233 imidazopyridazines Chemical class 0.000 description 1
• 239000000367 immunologic factor Substances 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 229960000905 indomethacin Drugs 0.000 description 1
• 230000004968 inflammatory condition Effects 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 208000037797 influenza A Diseases 0.000 description 1
• 238000002329 infrared spectrum Methods 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 239000012444 intercalating antibiotic Substances 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 201000002313 intestinal cancer Diseases 0.000 description 1
• 208000003243 intestinal obstruction Diseases 0.000 description 1
• 238000007917 intracranial administration Methods 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 208000002551 irritable bowel syndrome Diseases 0.000 description 1
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
• KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
• 210000001847 jaw Anatomy 0.000 description 1
• MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
• DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
• 229960000991 ketoprofen Drugs 0.000 description 1
• 201000010982 kidney cancer Diseases 0.000 description 1
• 210000003127 knee Anatomy 0.000 description 1
• 206010023497 kuru Diseases 0.000 description 1
• 201000003445 large cell neuroendocrine carcinoma Diseases 0.000 description 1
• 201000010901 lateral sclerosis Diseases 0.000 description 1
• 229940070765 laurate Drugs 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 229960001691 leucovorin Drugs 0.000 description 1
• GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
• 229960004338 leuprorelin Drugs 0.000 description 1
• CMJCXYNUCSMDBY-ZDUSSCGKSA-N lgx818 Chemical compound COC(=O)N[C@@H](C)CNC1=NC=CC(C=2C(=NN(C=2)C(C)C)C=2C(=C(NS(C)(=O)=O)C=C(Cl)C=2)F)=N1 CMJCXYNUCSMDBY-ZDUSSCGKSA-N 0.000 description 1
• 229940010454 licorice Drugs 0.000 description 1
• 239000004571 lime Substances 0.000 description 1
• 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
• 235000019421 lipase Nutrition 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 229920001684 low density polyethylene Polymers 0.000 description 1
• 239000004702 low-density polyethylene Substances 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 201000005296 lung carcinoma Diseases 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 208000037841 lung tumor Diseases 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 229940049920 malate Drugs 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 208000027202 mammary Paget disease Diseases 0.000 description 1
• IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 210000001595 mastoid Anatomy 0.000 description 1
• 231100000682 maximum tolerated dose Toxicity 0.000 description 1
• 238000000968 medical method and process Methods 0.000 description 1
• 208000028138 melanocytic neoplasm Diseases 0.000 description 1
• 230000009245 menopause Effects 0.000 description 1
• HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
• IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
• 229940095102 methyl benzoate Drugs 0.000 description 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
• LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
• OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
• 238000000386 microscopy Methods 0.000 description 1
• 210000004688 microtubule Anatomy 0.000 description 1
• 230000001617 migratory effect Effects 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 230000002438 mitochondrial effect Effects 0.000 description 1
• 230000011278 mitosis Effects 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 239000003607 modifier Substances 0.000 description 1
• 208000013734 mononeuritis simplex Diseases 0.000 description 1
• 201000005518 mononeuropathy Diseases 0.000 description 1
• 150000002772 monosaccharides Chemical class 0.000 description 1
• 210000004400 mucous membrane Anatomy 0.000 description 1
• 229940124303 multikinase inhibitor Drugs 0.000 description 1
• 210000002346 musculoskeletal system Anatomy 0.000 description 1
• 230000023105 myelination Effects 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
• HAYYBYPASCDWEQ-UHFFFAOYSA-N n-[5-[(3,5-difluorophenyl)methyl]-1h-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide Chemical compound C1CN(C)CCN1C(C=C1NC2CCOCC2)=CC=C1C(=O)NC(C1=C2)=NNC1=CC=C2CC1=CC(F)=CC(F)=C1 HAYYBYPASCDWEQ-UHFFFAOYSA-N 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
• 235000021096 natural sweeteners Nutrition 0.000 description 1
• 208000019382 nerve compression syndrome Diseases 0.000 description 1
• 229940053128 nerve growth factor Drugs 0.000 description 1
• 210000000944 nerve tissue Anatomy 0.000 description 1
• 208000007538 neurilemmoma Diseases 0.000 description 1
• 230000016273 neuron death Effects 0.000 description 1
• 230000003961 neuronal insult Effects 0.000 description 1
• 230000006576 neuronal survival Effects 0.000 description 1
• 201000009985 neuronitis Diseases 0.000 description 1
• 238000006386 neutralization reaction Methods 0.000 description 1
• 239000012299 nitrogen atmosphere Substances 0.000 description 1
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
• 208000030212 nutrition disease Diseases 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 229940049964 oleate Drugs 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
• 210000004248 oligodendroglia Anatomy 0.000 description 1
• 208000031237 olivopontocerebellar atrophy Diseases 0.000 description 1
• 231100000590 oncogenic Toxicity 0.000 description 1
• 230000002246 oncogenic effect Effects 0.000 description 1
• 239000006186 oral dosage form Substances 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 239000003960 organic solvent Substances 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 238000010979 pH adjustment Methods 0.000 description 1
• 238000004806 packaging method and process Methods 0.000 description 1
• 239000000123 paper Substances 0.000 description 1
• 201000010198 papillary carcinoma Diseases 0.000 description 1
• 230000003076 paracrine Effects 0.000 description 1
• 210000003681 parotid gland Anatomy 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 201000007285 pediatric fibrosarcoma Diseases 0.000 description 1
• 230000009518 penetrating injury Effects 0.000 description 1
• 208000028169 periodontal disease Diseases 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 239000008194 pharmaceutical composition Substances 0.000 description 1
• 229940049953 phenylacetate Drugs 0.000 description 1
• WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
• XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
• 229950010773 pidilizumab Drugs 0.000 description 1
• 108010026735 platelet protein P47 Proteins 0.000 description 1
• 230000010287 polarization Effects 0.000 description 1
• 238000003752 polymerase chain reaction Methods 0.000 description 1
• 208000019629 polyneuritis Diseases 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 230000002980 postoperative effect Effects 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 108010083945 potassium channel protein TREK-1 Proteins 0.000 description 1
• 239000001508 potassium citrate Substances 0.000 description 1
• 229960002635 potassium citrate Drugs 0.000 description 1
• 235000011082 potassium citrates Nutrition 0.000 description 1
• 208000001282 primary progressive aphasia Diseases 0.000 description 1
• 208000032207 progressive 1 supranuclear palsy Diseases 0.000 description 1
• 201000002241 progressive bulbar palsy Diseases 0.000 description 1
• 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 208000023958 prostate neoplasm Diseases 0.000 description 1
• 239000003207 proteasome inhibitor Substances 0.000 description 1
• 229960000856 protein c Drugs 0.000 description 1
• 201000000196 pseudobulbar palsy Diseases 0.000 description 1
• 238000010926 purge Methods 0.000 description 1
• 238000004445 quantitative analysis Methods 0.000 description 1
• 229960001285 quercetin Drugs 0.000 description 1
• 235000005875 quercetin Nutrition 0.000 description 1
• 238000011127 radiochemotherapy Methods 0.000 description 1
• 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 206010038038 rectal cancer Diseases 0.000 description 1
• 208000020615 rectal carcinoma Diseases 0.000 description 1
• 210000000664 rectum Anatomy 0.000 description 1
• 230000010410 reperfusion Effects 0.000 description 1
• 238000002271 resection Methods 0.000 description 1
• 210000002345 respiratory system Anatomy 0.000 description 1
• 102000027483 retinoid hormone receptors Human genes 0.000 description 1
• 108091008679 retinoid hormone receptors Proteins 0.000 description 1
• 238000003757 reverse transcription PCR Methods 0.000 description 1
• 238000004007 reversed phase HPLC Methods 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 230000000552 rheumatic effect Effects 0.000 description 1
• 206010039083 rhinitis Diseases 0.000 description 1
• 229960000215 ruxolitinib Drugs 0.000 description 1
• HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
• 235000019204 saccharin Nutrition 0.000 description 1
• 229960001860 salicylate Drugs 0.000 description 1
• 238000004626 scanning electron microscopy Methods 0.000 description 1
• 206010039667 schwannoma Diseases 0.000 description 1
• 208000007771 sciatic neuropathy Diseases 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 229950010746 selumetinib Drugs 0.000 description 1
• CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
• 229950003647 semaxanib Drugs 0.000 description 1
• WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 208000007056 sickle cell anemia Diseases 0.000 description 1
• 230000008054 signal transmission Effects 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 238000004088 simulation Methods 0.000 description 1
• 229960000714 sipuleucel-t Drugs 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 208000000587 small cell lung carcinoma Diseases 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• 235000017550 sodium carbonate Nutrition 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 229960001790 sodium citrate Drugs 0.000 description 1
• 229960001462 sodium cyclamate Drugs 0.000 description 1
• 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 229960003339 sodium phosphate Drugs 0.000 description 1
• 239000012064 sodium phosphate buffer Substances 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 208000014653 solitary fibrous tumor Diseases 0.000 description 1
• 238000002336 sorption--desorption measurement Methods 0.000 description 1
• 208000018198 spasticity Diseases 0.000 description 1
• 238000004611 spectroscopical analysis Methods 0.000 description 1
• 210000003594 spinal ganglia Anatomy 0.000 description 1
• 201000000270 spindle cell sarcoma Diseases 0.000 description 1
• 208000011584 spitz nevus Diseases 0.000 description 1
• SETMGIIITGNLAS-UHFFFAOYSA-N spizofurone Chemical compound O=C1C2=CC(C(=O)C)=CC=C2OC21CC2 SETMGIIITGNLAS-UHFFFAOYSA-N 0.000 description 1
• 229950001870 spizofurone Drugs 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 201000000498 stomach carcinoma Diseases 0.000 description 1
• 208000003755 striatonigral degeneration Diseases 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 150000005846 sugar alcohols Chemical class 0.000 description 1
• IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
• 210000004243 sweat Anatomy 0.000 description 1
• 230000008961 swelling Effects 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 210000001779 taste bud Anatomy 0.000 description 1
• 210000001738 temporomandibular joint Anatomy 0.000 description 1
• 150000003512 tertiary amines Chemical class 0.000 description 1
• 201000003120 testicular cancer Diseases 0.000 description 1
• 239000000892 thaumatin Substances 0.000 description 1
• 235000010436 thaumatin Nutrition 0.000 description 1
• 230000001732 thrombotic effect Effects 0.000 description 1
• 229940032953 thyroid therapy drug Drugs 0.000 description 1
• 208000013076 thyroid tumor Diseases 0.000 description 1
• 235000015149 toffees Nutrition 0.000 description 1
• 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000002110 toxicologic effect Effects 0.000 description 1
• 231100000759 toxicological effect Toxicity 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 239000003558 transferase inhibitor Substances 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• 238000000411 transmission spectrum Methods 0.000 description 1
• 229950007217 tremelimumab Drugs 0.000 description 1
• 235000013337 tricalcium citrate Nutrition 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 231100000397 ulcer Toxicity 0.000 description 1
• 210000003932 urinary bladder Anatomy 0.000 description 1
• 201000005112 urinary bladder cancer Diseases 0.000 description 1
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
• 206010046766 uterine cancer Diseases 0.000 description 1
• 210000004291 uterus Anatomy 0.000 description 1
• 229940070710 valerate Drugs 0.000 description 1
• NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
• 239000002435 venom Substances 0.000 description 1
• 210000001048 venom Anatomy 0.000 description 1
• 231100000611 venom Toxicity 0.000 description 1
• 238000002460 vibrational spectroscopy Methods 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 208000009935 visceral pain Diseases 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 230000008673 vomiting Effects 0.000 description 1
• 235000020234 walnut Nutrition 0.000 description 1
• 238000010792 warming Methods 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 230000003313 weakening effect Effects 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 235000010447 xylitol Nutrition 0.000 description 1
• 239000000811 xylitol Substances 0.000 description 1
• HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
• 229960002675 xylitol Drugs 0.000 description 1